Onderneming Carbylan Therapeutics Inc Nasdaq
Aandelen
US1413841073
Farmaceutische producten
Vakgebied
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Ed Feener
FOU | Founder | 64 | 26-03-04 |
Ben Palleiko
CEO | Chief Executive Officer | 58 | 01-08-16 |
Paul Audhya
CTO | Chief Tech/Sci/R&D Officer | 51 | 03-05-21 |
Ryan Baker
IRC | Investor Relations Contact | - | 01-05-23 |
Nicole Sweeny
PRN | Corporate Officer/Principal | 49 | 25-07-23 |
Christopher Yea
PRN | Corporate Officer/Principal | 61 | 01-11-16 |
Mike Smith
PRN | Corporate Officer/Principal | - | 01-02-16 |
Rachel Morten
LAW | General Counsel | - | 01-01-16 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Brian Pereira
CHM | Chairman | 65 | 01-02-19 |
Ben Palleiko
CEO | Chief Executive Officer | 58 | 01-08-16 |
Albert Cha
BRD | Director/Board Member | 51 | 01-01-16 |
Edward Unkart
BRD | Director/Board Member | 74 | 01-12-14 |
Nancy Stuart
BRD | Director/Board Member | 65 | 18-03-21 |
Patrick Treanor
BRD | Director/Board Member | - | 26-05-22 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 42 188 296 | 41 670 541 ( 98,77 %) | 0 | 98,77 % |
Bedrijfsgegevens
KalVista Pharmaceuticals, Inc.
55 Cambridge Parkway Suite 901 East
02142, Cambridge
+857 999 0075
http://www.kalvista.comSector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+0,82% | 91,94 mld. | |
-1,32% | 38,74 mld. | |
-12,88% | 32,82 mld. | |
+64,77% | 26,66 mld. | |
-16,31% | 15,32 mld. | |
-5,78% | 13,3 mld. | |
-11,38% | 11,65 mld. | |
-49,84% | 10,12 mld. | |
+5,24% | 9,06 mld. |